
# Allergy vaccines: the importance of the active principle

more important than the pharmaceutical form, either tablets, drops or injections!

LOFARMA S.p.A. 2010


### The Allergen





This is a simplification of an allergen molecule, for example of a weed.

### The Carbamylated Allergoid



This is a simplification of an allergoid molecule, a chemical modification of an allergen.

The Carbamylated Allergoid is obtained by carbamylation with potassium cyanate at alkaline pH, a reaction that leads to a substantial substitution of the allergen lysine aminogroups: a well-definite active principle.



Dramatic reduction of specific IgE linking

reduced allergenic activity

**SAFETY** 




Resistance to enzymatic degradation

carbamylated allergoid remains active

"high doses" are not necessary.

**EFFECTIVE DOSES** 






PRESERVATION of molecular sizes

Carbamylated Allergoid is a Monomeric Allergoid

FIT for SLIT



IRREVERSIBILITY of carbamylation

NO back to native allergen


**SAFETY** 

#### selected references

#### Synopsis of published Lais studies Part 1: study design


AUTHOR	JOURNAL	Study	Adults/ Children	No. Patients	Diseases*	Allergen	Treatment	Tablets/Drops
Bordignon	Giorn It Allergol Immmunol Clin 1994;4:153-159	DBPC	adults, children	60	OR and/or A	Grass	preseasonal	Tab
Pacor	Rec Prog Med 1996;87(1):4-6	open	adults	34	OR	Grass	preseasonal	Tab
Caffarelli	Allergy 2000;55:1142-7	DBPC	children	48 (24A+24P)	R, C or A	Grass	preseasonal	Tab
Lombardi	J Invest Allergol Clin Immunol 2001; 11:41-45	open	adults	51 (26A+25C)	RC and/or A	Grass	preseasonal	Tab
Palma-Carlos	Allergol Immunopathol 2006;34(5):194-198	DBPC	adults	33	R with or without A	Grass	preseasonal	Tab
Burastero	Ann All Ast Imm 2006;100:343-350	open	adults	11	R	Grass	preseasonal	Tab
Pacor	Rec Prog Med 1995;86(12):489-91	open	adults	14	A	Mites	continuous	Tab
La Rosa	Not Allergol 1996;15:45-46	open	children	30	A and/or RC	Mites	continuous	Tab
Passalacqua	The Lancet 1998;351:629-32	DBPC	adults	20 (10A+10P)	RC	Mites	continuous	Tab
Marogna	Int Journ Imm Pharm 2001;14:93-101	observational (SLIT, SIT, intranasal)	adults	29 A + 12 C (SLIT)	OR with or without A	Mites	continuous	Tab
Passalacqua	Allergy 2006;61:849-854	DBPC	adults	56 ( A+ P)	R	Mites	continuous	Tab
Cosmi	Clin Exp All 2006;36:261-292	open	adults	25 (A+C)	R with or without A	Mites	continuous	Tab
lppoliti	Pediatr Allergy Immunol 2006;17:337-345	open	children	40	Α	Mites	continuous	Drops
Marogna	Int Arc All Imm 2007;142:70-78	retrospective	adults	65 (53 A+12C)	R	Mitos	continuous	Tab
Marogna	Eur Ann Allergy Clin Immunol 2008;40:22-29	retrospective	adults	101 (57 A+44C)	R	Mites	continuous	Tab
Ariano	Invest Allergol Clin Immunol 1996;8(3):155-160	DBPC	adults	30 (15A+15P)	R with or without A	Parietaria	pre-co-seasonal	Tab
D'Anneo	Allergol Immunopathol 2008;36(2):79-84	open	adults	65 (24A+21A+2 1C)	R and/or A	Parietaria	coseasonal	Tab
Lombardi	Allergy 2001;56:989-992	open (safety)	adults	198	R and/or A	Mites(69), Grass(75), Olive(1), birch(4), Parietana(48),	preseasonal or continuos	Tab
Marogna	Eur Ann All Imm Clin 2003;35(4):133-140	observational (SLIT, SIT, intranasal)	adults, children	106 A (Lais)+ 170 C	R and A	Mites(44), Grass(38), birch(32)	continuos	Tab
Rossi	Giorn It Allergol Immunol Clin 2002; 12: 221-228	open (safety)	adults	13	R and/or A	Grass + Mites		Tab
Arena	Int Journ Imm Pharm 2003;16:277-282	open	adults	60	R with or without A	Mites(29), Grass(5), Olive(2), Parietaria(24)	preseasonal or continuos	Tab
Agostinis	Allergy 2005;60:133	open (safety)	children	36	A or R	Mites, Grass	continuous	Drops
Gammeri	Allergol Immunopathol 2005;33(3):142-4	open (safety)	adults, children	105 (28 c+77a)	RorA	Mites(56), Grass(15), Parietaria(34)		Tab
Rossi	Int J Immunopathol Pharmacol 2005;18:277-285	open (safety)	adults	45	RC and/or A	Grass + Mites		Tab
Giordano	Eur Ann All Imm Clin 2006;38(9):310-312	open	adults	39	R with or without A	Mites(27), Grass(7), Olive(3), Cat(1), Parietaria(1)	continuous	Tab
La Grutta	Eur Ann Clin Immunol 2007;39:40-44	open	adults/ children	56 (33A+ 23C)	A with or without R	Mitos . Parietaria	continuous	Tab
Burastero	Int J Immunopathol Pharmacol 2009; 22:343-352	open	adults	11	R	Birch	pre-co-seasonal	Tab
Mezei	Not Allergol 1996;15:40-44	DBPC	adults/ children	60 (30ad+30child) 20A+10P in each group	RC with or without A	Ragweed	pre-co- sessonal	Tab
Ariano	Eur Ann All Imm Clin 2005;37(3):103-108	open	adults	30 (20A+10C)	RC and/or A	Cypress	pre-co- seasonal	Drops
Rolla	EAACI 2009	open	adults	21	RC and/or A	Birch	pre-co-seasonal	Tab

			reatment	Results	Results	Results Mch	Cumulative dosages in AU/year
AUTHOR Bordignon	Giorn It Allergol Immmunol Clin	14 weeks	Maintenance AU 1000/week	Symptoms	Drugs	mcn	36,500
	1994;4:153-159 Rec Prog Med	14 weeks	1000/week	reduction	reduction		36,500
Pacor	1996;87(1):4-6 Allergy				reduction		300.000
Caffarelli	2000;55:1142-7	7 weeks	3000/week	reduction	-		37,250
Lombardi	J Invest Allergol Clin Immunol 2001; 11:41-45	14 weeks		reduction	reduction	reduction bronch. reac.	36,000
Palma-Carlos	Allergel Immunopathol 2006;34(5):194-198	14 weeks	2000/week	reduction	reduction	reduction nasal reac.	40,500
Burastero	Ann All Ast Imm 2008;100:343-350		14000/week	153	878		120,000
Pacor	Rec Prog Med 1995;86(12):489-91	14 weeks	1000/week	reduction	•	reduction	62,500
La Rosa	Not Allergol 1996:15:45-46	3 weeks	300/week	reduction	reduction		23,775
Passalacqua	The Lancet 1998;351:629-32	14 weeks	4000/week	reduction	reduction	reduction ICAM1, ECP	176,500
Marogna	Int Journ Imm Pharm 2001;14:93-101	14 weeks	2000/week	reduction	reduction	reduction bronch reac.	100,000
Passalacqua	Allergy 2006;61:849-854	4 weeks	2000/week	reduction	reduction	quality of life improvement.	116,000
Cosmi	Clin Exp All 2006;36:261-292	8 weeks	1000/week	reduction		immunological eval. (IL-10)	60,000
Ippoliti	Pediatr Allergy Immunol 2006;17:337-345	4 weeks	1800/week	reduction		reduction bronch. reac.	43,950
Marogna	Int Arc All Imm 2007;142:70-78	14 weeks	1000/week	reduction		reduction bronch. reac.	82,500 (1 year) 218,500 (4 years)
Marogna	Eur Ann Allergy Clin Immunol 2008;40:22-29	14 weeks	1000/week	reduction		reduction bronch, reac.	62,500
Ariano	Invest Allergol Clin Immunol 1998;8(3):155-160	14 weeks	2000/week	reduction	reduction	reduction nasal reac.	72,525
D'Anneo	Allergol Immunopathol 2008;36(2):79-84	3 days	1000 or 3000/week	reduction (VAS)	reduction	reduction bronch. reac.	32,000 or 84,00
Lombardi	Allergy 2001;56:989-992	8 weeks	2000/week	•	1.4		20,850 or 104,800
Marogna	Eur Ann All Imm Clin 2003;35(4):133-140	14 weeks	1000/week	reduction	reduction	reduction bronch reac	62,500
Rossi	Giorn It Allergol Immunol Clin 2002; 12: 221-228	2 hours	2000/week				
Arena	Int J Immunopathol Pharmacol 2003;16:277-282	14 weeks	4000/week	reduction	reduction		176,500
Agostinis	Allergy 2005;60:133	3 weeks	4200/week	reduction			216,000
Gammeri	Allergol Immunopathol 2005;33(3):142-4	20 minutes	2000/week	- 51			
Rossi	Int J Immunopathol Pharmacol 2005;18:277-285	20 minutes	2000/week				
Giordano	Eur Ann All Imm Clin 2006;38(9):310-312	4 days	2000/week	reduction (VAS)	reduction		109,000
La Grutta	Eur Ann Clin Immunol 2007;39:40-44	16 days	2000/week	reduction	reduction	reduction bronch. reac.	110,000
Burastero	Int J Immunopathol Pharmacol 2009;22:343-352		15,000/month	reduction	reduction	immunological eval. (IL-10)	90,000
Mezei	Not Allergol 1996;15:40-44	8 weeks	2000x9 5 week 1000x 9 week	reduction	reduction	reduction nasal reac. signific. in ad.	33300
Ariano	Eur Ann All Imm Clin 2005;37(3):103-108	16 days	900/week	reduction	reduction	reduction nasal reac.	22,900
Rolla	EAACI 2009		6000/week or 2000/week	reduction	reduction		120,000 or 208,000
Fancello	EAACI 2008	4 days	1000/week	reduction (VAS)			57,000



1997 Bagnasco, JACI


1°study on kinetics



1998
Passalacqua, Lancet


1°study with tablets,

allergoid tablets



2000 Caffarelli, Allergy


1°study with tablets in children



2001 Bagnasco, Allergy


Comparison between allergoid tablets

VSallergen in tabletsand in solution




2004 Lombardi, JACI

Adherence to allergoid SLIT




2005 Agostinis, <u>Allergy</u>

Safety in children




2006 Cosmi, Clin Exp Allergy

Allergoid SLIT mechanism



2009
D'Anneo, Int J Imm Pharm
Allergoid SLIT safety
and tolerability with
4-day
induction phase



2010 Passali, Acta ORL

Allergoid SLIT safety and tolerability without induction phase

#### A final snapshot on the market...

#### Allergen SLIT

Alk - Grazax

Alk - SLITOne

Alk - SLITOne plus

Allergopharma - Allerslit

Bencard - Oralvac

HAL – Sublivac

Novartis - Tol SL

Roxall - Sulgen spray

Stallergenes - Oralair

Stallergenes - Staloral

Themocare - Allerbio sublingual

#### Allergoid SLIT

Lofarma - Lais tablets

Lofarma - Lais drops